Natera Inc (NTRA) Stock Price, Quote & News

Company Profile

Natera, Inc., a diagnostics company, provides molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders; Spectrum, preimplantation genetic tests for couples und...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 650 980 9190

Website: www.natera.com

Address:

13011 McCallen Pass, Building A Suite 100, Austin, United States

THE_Monkey_Banana_Genius Oct. 6 at 3:21 PM

$ASTS $GH $NTRA $RKLB $TTWO noice!

1 · Reply

RegertsOnly Oct. 5 at 2:26 PM

$NTRA Genomic sequencing leader. Breaking above consolidation. Volume expansion noted. Relative strength improving.

0 · Reply

SweepCastApp Oct. 3 at 9:40 PM

$NTRA: Unusual Options Activity Alerted CALL flow observed 31x contracts at Strike price of $160 Exp on 12/19/2025 with Premium of $46K and showing BEARISH Sentiment

0 · Reply

MoneyGroupLLC Oct. 3 at 10:13 AM

Enter: $NTRA NOV 21 2025 $165 CALLS Buy in Price: $10.46 - $11.10 Take Profit: $12.87 Stop Bleeding: $9.20 ROI Potential: 23% Exit Within: 233 Minutes https://moneygroup.us/alerts

0 · Reply

MoneyGroupLLC Oct. 1 at 9:03 PM

Enter: $NTRA NOV 21 2025 $165 CALLS Buy in Price: $12.70 - $13.20 Take Profit: $23.24 Stop Bleeding: $11.18 ROI Potential: 83% Exit Within: 175 Minutes https://moneygroup.us/alerts

0 · Reply

SweepCastApp Oct. 1 at 5:42 PM

$NTRA: Unusual Options Activity Alerted CALL flow observed 25x contracts at Strike price of $155 Exp on 10/17/2025 with Premium of $28K and showing BULLISH Sentiment

0 · Reply

MoneyGroupLLC Sep. 30 at 8:12 AM

Enter: $NTRA NOV 21 2025 $165 CALLS Buy in Price: $12.30 - $12.92 Take Profit: $18.57 Stop Bleeding: $10.82 ROI Potential: 51% Exit Within: 183 Minutes https://moneygroup.us/alerts

0 · Reply

SweepCastApp Sep. 29 at 7:39 AM

$NTRA: Unusual Options Activity Alerted PUT flow observed 210x contracts at Strike price of $150 Exp on 10/17/2025 with Premium of $48K and showing BEARISH Sentiment

0 · Reply

MoneyGroupLLC Sep. 28 at 10:24 PM

Enter: $NTRA NOV 21 2025 $165 CALLS Buy in Price: $12.30 - $14.60 Take Profit: $29.15 Stop Bleeding: $10.82 ROI Potential: 137% Exit Within: 362 Minutes https://moneygroup.us/alerts

0 · Reply

MoneyGroupLLC Sep. 26 at 9:57 PM

Enter: $NTRA OCT 17 2025 $165 CALLS Buy in Price: $6.10 - $6.41 Take Profit: $8.48 Stop Bleeding: $5.37 ROI Potential: 39% Exit Within: 80 Minutes https://moneygroup.us/alerts

0 · Reply

Enrollment Tops 1,600 in Natera's EXPAND Trial of Single Gene NIPT

Sep 30, 2025, 8:00 AM EDT - 7 days ago

Natera Announces Publication of Signatera™ Validation Study in Testicular Cancer

Sep 29, 2025, 8:00 AM EDT - 8 days ago

Signatera™ Surveillance Testing Identified 100% of Uterine Cancer Recurrences in Advance of Imaging, New Study Shows

Sep 24, 2025, 10:53 AM EDT - 12 days ago

Natera, Inc. (NTRA) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript

Sep 15, 2025, 10:10 AM EDT - 21 days ago

Can Natera Stock Reach $500?

Sep 10, 2025, 12:31 PM EDT - 26 days ago

Natera, Inc. (NTRA) Presents At Baird Global Healthcare Conference 2025 Transcript

Sep 2, 2025, 2:40 PM EDT - 4 weeks ago

Natera: A Buy As Positive Growth And Cashflow Outweigh Unprofitability

Aug 29, 2025, 8:18 AM EDT - 5 weeks ago

Natera Provides Update on Patent Litigation with NeoGenomics

Aug 28, 2025, 8:00 AM EDT - 5 weeks ago

Signatera™ Test Selected for NRG-Sponsored Phase III ARCHER Trial in Bladder Cancer

Aug 25, 2025, 8:00 AM EDT - 6 weeks ago

Natera to Present Signatera™ Data at the IASLC World Conference on Lung Cancer

Aug 22, 2025, 6:04 AM EDT - 6 weeks ago

Natera Technology Featured in 300+ Peer-Reviewed Publications, Underscoring Scientific Leadership in Precision Medicine

Aug 22, 2025, 5:00 AM EDT - 6 weeks ago

Natera Launches Proprietary AI Foundation Models to Accelerate Diagnostic and Therapeutic Innovation

Aug 18, 2025, 6:00 AM EDT - 7 weeks ago

IMvigor011 Bladder Cancer Trial Achieves Positive Results, with Signatera™ Strongly Predicting Adjuvant Immunotherapy Benefit

Aug 8, 2025, 4:08 PM EDT - 2 months ago

Natera shares surge 17% after strong Q2 results and upgraded guidance

Aug 7, 2025, 10:43 PM EDT - 2 months ago

Natera, Inc. (NTRA) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 2 months ago

Natera Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 7:00 AM EDT - 2 months ago

Natera Launches Fetal Focus™: A Noninvasive Prenatal Test for Inherited Conditions

Aug 1, 2025, 7:00 AM EDT - 2 months ago

Natera Highlights Latest Prospera™ Data at WTC 2025; 16 Abstracts Including Five Oral Presentations

Jul 31, 2025, 7:00 AM EDT - 2 months ago

Natera to Report Its Second Quarter Results on August 7, 2025

Jul 29, 2025, 7:00 AM EDT - 2 months ago

Natera Announces Launch of ABCSG 61 (“TEODOR”), a Randomized Controlled Trial of Signatera™ in Early-Stage Breast Cancer

Jul 24, 2025, 8:00 AM EDT - 2 months ago

PEDAL Study Successful, Shows Monitoring with Prospera™ Kidney Provides Accurate Prognosis of Long-Term Clinical Outcomes Following Rejection; Now Published in AJT

Jul 7, 2025, 7:00 AM EDT - 3 months ago

Natera Presents Data at ESMO GI on its Tissue-Free Latitude™ MRD* Assay, Demonstrating Excellent Overall Performance in Colorectal Cancer

Jul 1, 2025, 4:05 PM EDT - 3 months ago

Natera to Present Clinical and Economic Utility of Signatera at ESMO GI, Highlights Innovations in MRD

Jun 4, 2025, 7:00 AM EDT - 4 months ago

Natera Announces Medicare Coverage for Signatera™ Genome

Jun 2, 2025, 4:05 PM EDT - 4 months ago

SignateraTM Genome Clinical Performance Highlighted at ASCO 2025

May 22, 2025, 5:08 PM EDT - 4 months ago

Natera to Present over 25 Signatera™ Studies at 2025 ASCO Annual Meeting

May 16, 2025, 8:41 AM EDT - 5 months ago

Natera: The Clues In Q1 Earnings

May 8, 2025, 8:58 PM EDT - 5 months ago

Natera, Inc. (NTRA) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:05 PM EDT - 5 months ago

Natera Reports First Quarter 2025 Financial Results

May 8, 2025, 10:30 AM EDT - 5 months ago

Signatera Data From I-SPY 2 Trial to Be Presented at ESMO Breast Annual Congress

May 7, 2025, 7:00 AM EDT - 5 months ago

Prospera™ Heart Test with DQS Outperforms dd-cfDNA Percentage in Detecting Allograft Rejection, New AJT Publication Shows

May 5, 2025, 7:00 AM EDT - 5 months ago

Largest Sarcoma Study to Date with ctDNA Analysis Demonstrates Excellent Performance for Signatera

May 1, 2025, 7:00 AM EDT - 5 months ago

Natera to Report its First Quarter Results on May 8, 2025

Apr 29, 2025, 4:05 PM EDT - 5 months ago

Prospective DEFINE-HT Study Demonstrates that Prospera™ Heart is Predictive of Clinical Outcomes and Outperforms Biopsy in Predicting Graft Dysfunction

Apr 29, 2025, 11:45 AM EDT - 5 months ago

Baron Health Care Fund Q1 2025 Top Net Purchases And Sales

ACLX ISRG MASI MCK PEN TMO UNH

Apr 24, 2025, 7:00 AM EDT - 5 months ago

Natera Announces Broad Clinical Launch of Ultra-Sensitive Signatera™ Genome MRD Test

Apr 22, 2025, 4:05 PM EDT - 5 months ago

Natera To Present Data from 8 Studies at 2025 AACR Annual Meeting

Mar 25, 2025, 7:00 AM EDT - 7 months ago

DEFINE-HT Selected for Late-Breaking Oral Presentation at ISHLT Annual Meeting

Mar 17, 2025, 11:52 AM EDT - 7 months ago

Natera: Growth Looks Unstoppable, Positive EPS Just A Matter Of Time

Mar 10, 2025, 8:00 AM EDT - 7 months ago

Natera Announces Enrollment of First Patients in the HEROES Clinical Trial in Metastatic HER2+ Breast Cancer

Mar 4, 2025, 7:00 AM EST - 7 months ago

Natera Expands Intellectual Property Portfolio With New Patents in Tumor-Informed MRD

Feb 28, 2025, 12:23 AM EST - 7 months ago

Natera, Inc. (NTRA) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 4:05 PM EST - 7 months ago

Natera Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 25, 2025, 6:00 AM EST - 8 months ago

Natera Announces Medicare Coverage of Signatera™ for Surveillance in Lung Cancer

Feb 18, 2025, 9:00 AM EST - 8 months ago

Natera to Report its Fourth Quarter and Full Year Results on February 27, 2025

Feb 10, 2025, 7:00 AM EST - 8 months ago

NCCN Strengthens Guidance on ctDNA in Colon Cancer, Rectal Cancer, and Merkel Cell Carcinoma

Feb 3, 2025, 7:00 AM EST - 8 months ago

Natera Announces National Commercial Coverage for its Fetal RhD NIPT

Jan 25, 2025, 10:05 AM EST - 9 months ago

Natera Announces Successful Readout of Randomized, Phase III CALGB (Alliance) / SWOG 80702 Clinical Trial in Colorectal Cancer

Jan 21, 2025, 6:05 PM EST - 9 months ago

Natera to Present New Data at the 2025 ASCO GI Symposium

Jan 17, 2025, 9:00 AM EST - 9 months ago

Natera CEO Steve Chapman Recognized as a 2024 Top Healthcare Technology CEO and BioTechnology Innovator of the Year

THE_Monkey_Banana_Genius Oct. 6 at 3:21 PM

$ASTS $GH $NTRA $RKLB $TTWO noice!

1 · Reply

RegertsOnly Oct. 5 at 2:26 PM

$NTRA Genomic sequencing leader. Breaking above consolidation. Volume expansion noted. Relative strength improving.

0 · Reply

SweepCastApp Oct. 3 at 9:40 PM

$NTRA: Unusual Options Activity Alerted CALL flow observed 31x contracts at Strike price of $160 Exp on 12/19/2025 with Premium of $46K and showing BEARISH Sentiment

0 · Reply

MoneyGroupLLC Oct. 3 at 10:13 AM

Enter: $NTRA NOV 21 2025 $165 CALLS Buy in Price: $10.46 - $11.10 Take Profit: $12.87 Stop Bleeding: $9.20 ROI Potential: 23% Exit Within: 233 Minutes https://moneygroup.us/alerts

0 · Reply

MoneyGroupLLC Oct. 1 at 9:03 PM

Enter: $NTRA NOV 21 2025 $165 CALLS Buy in Price: $12.70 - $13.20 Take Profit: $23.24 Stop Bleeding: $11.18 ROI Potential: 83% Exit Within: 175 Minutes https://moneygroup.us/alerts

0 · Reply

SweepCastApp Oct. 1 at 5:42 PM

$NTRA: Unusual Options Activity Alerted CALL flow observed 25x contracts at Strike price of $155 Exp on 10/17/2025 with Premium of $28K and showing BULLISH Sentiment

0 · Reply

MoneyGroupLLC Sep. 30 at 8:12 AM

Enter: $NTRA NOV 21 2025 $165 CALLS Buy in Price: $12.30 - $12.92 Take Profit: $18.57 Stop Bleeding: $10.82 ROI Potential: 51% Exit Within: 183 Minutes https://moneygroup.us/alerts

0 · Reply

SweepCastApp Sep. 29 at 7:39 AM

$NTRA: Unusual Options Activity Alerted PUT flow observed 210x contracts at Strike price of $150 Exp on 10/17/2025 with Premium of $48K and showing BEARISH Sentiment

0 · Reply

MoneyGroupLLC Sep. 28 at 10:24 PM

Enter: $NTRA NOV 21 2025 $165 CALLS Buy in Price: $12.30 - $14.60 Take Profit: $29.15 Stop Bleeding: $10.82 ROI Potential: 137% Exit Within: 362 Minutes https://moneygroup.us/alerts

0 · Reply

MoneyGroupLLC Sep. 26 at 9:57 PM

Enter: $NTRA OCT 17 2025 $165 CALLS Buy in Price: $6.10 - $6.41 Take Profit: $8.48 Stop Bleeding: $5.37 ROI Potential: 39% Exit Within: 80 Minutes https://moneygroup.us/alerts

0 · Reply

SweepCastApp Sep. 26 at 1:00 AM

$NTRA: SWEEP CALL activity detected 117 @ 9.80, Strike 160.0, Exp 10/17/2025, Premium $114,625, Sentiment BULLISH

0 · Reply

MoneyGroupLLC Sep. 25 at 11:13 AM

Enter: $NTRA OCT 17 2025 $170 CALLS Buy in Price: $6.76 - $7.90 Take Profit: $15.95 Stop Bleeding: $5.95 ROI Potential: 136% Exit Within: 374 Minutes https://moneygroup.us/alerts

0 · Reply

MoneyGroupLLC Sep. 24 at 3:36 PM

Enter: $NTRA OCT 17 2025 $175 CALLS Buy in Price: $8.30 - $11.20 Take Profit: $26.54 Stop Bleeding: $9.86 ROI Potential: 137% Exit Within: 125 Minutes https://moneygroup.us/alerts

0 · Reply

SilverEagle Sep. 23 at 1:26 PM

$NTRA 👀

0 · Reply

MoneyGroupLLC Sep. 23 at 12:41 AM

Enter: $NTRA OCT 17 2025 $180 CALLS Buy in Price: $7.30 - $9.50 Take Profit: $13.51 Stop Bleeding: $6.42 ROI Potential: 85% Exit Within: 357 Minutes https://moneygroup.us/alerts

0 · Reply

JarvisFlow Sep. 22 at 12:51 PM

Wells Fargo has updated their rating for Natera ( $NTRA ) to Equal-Weight with a price target of 175.

0 · Reply

MoneyGroupLLC Sep. 22 at 9:26 AM

Enter: $NTRA OCT 17 2025 $185 CALLS Buy in Price: $5.90 - $8.30 Take Profit: $10.56 Stop Bleeding: $5.19 ROI Potential: 79% Exit Within: 113 Minutes https://moneygroup.us/alerts

0 · Reply

MoneyGroupLLC Sep. 20 at 9:35 PM

Enter: $NTRA OCT 17 2025 $185 CALLS Buy in Price: $5.90 - $8.30 Take Profit: $10.56 Stop Bleeding: $5.19 ROI Potential: 79% Exit Within: 113 Minutes https://moneygroup.us/alerts

1 · Reply

StageAnalysis Sep. 20 at 8:52 PM

Stage Analysis Screener – Stage 2 Breakouts, Transitions & Continuation Breakouts SEI, $NTRA, STEP, NTLA, $PLUG, CVLT, HMY, $CLSK, STLD, MTB, ALL, SWKS, LAES, CRNC, $PANW, AMR, VCYT, KRYS, ACIW, ABT, APPN, PONY Filters: Stage: 2A, 2, 2B Stage Change: Stage Changed Market Cap: +Mini (over $300MLN) WCR: Close in Upper Quarter of Bar Avg $ Volume: Over 100M Sort order: SATA Score / Mansfield RS The purpose of this scan is to find stocks whose major Stage changed this week to Stage 2 from either Stage 1,3 or 4.

0 · Reply

MoneyGroupLLC Sep. 18 at 8:58 PM

Enter: $NTRA OCT 17 2025 $180 CALLS Buy in Price: $5.90 - $6.70 Take Profit: $9.15 Stop Bleeding: $5.19 ROI Potential: 55% Exit Within: 207 Minutes https://moneygroup.us/alerts

0 · Reply

PMartinez1 Sep. 12 at 7:13 PM

$NTRA loaded on puts over the last week. Cross my fingers.

1 · Reply

THE_Monkey_Banana_Genius Sep. 12 at 7:08 PM

$ASTS $GH $NTRA $RKLB $TTWO not too shabby

5 · Reply

Market Cap	22.97B
Revenue (ttm)	1.70B
Net Income (ttm)	-190.43M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-11.22%
Debt to Equity Ratio	0.06

Volume	1,424,600
Avg Vol	1,300,730
Day's Range	N/A - N/A
Shares Out	137.25M
Stochastic %K	82%
Beta	1.74
Analysts	Strong Sell
Price Target	$204.35